Nurix Therapeutics (NASDAQ:NRIX) Given New $27.00 Price Target at Royal Bank of Canada

Nurix Therapeutics (NASDAQ:NRIX) had its price objective upped by Royal Bank of Canada from $26.00 to $27.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Several other research firms also recently commented on NRIX. Stifel Nicolaus increased their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research report on Wednesday. BTIG Research began coverage on shares of Nurix Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $35.00 price target for the company. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a “buy” rating and a $41.00 price target for the company. JPMorgan Chase & Co. decreased their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, BMO Capital Markets began coverage on shares of Nurix Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $35.00 price target for the company. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.71.

Nurix Therapeutics Stock Up 0.5 %

NASDAQ NRIX opened at $19.65 on Wednesday. Nurix Therapeutics has a 1-year low of $7.79 and a 1-year high of $29.56. The firm’s fifty day simple moving average is $20.20 and its 200-day simple moving average is $22.42.

Nurix Therapeutics (NASDAQ:NRIX) last posted its earnings results on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, equities analysts anticipate that Nurix Therapeutics will post -2.81 earnings per share for the current year.

Insiders Place Their Bets

In other Nurix Therapeutics news, CFO Houte Hans Van sold 3,546 shares of the firm’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at $818,818.72. This trade represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank increased its holdings in shares of Nurix Therapeutics by 30.6% in the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after purchasing an additional 559 shares in the last quarter. Quarry LP increased its holdings in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 1,098.4% in the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after purchasing an additional 4,119 shares in the last quarter. Finally, Quest Partners LLC increased its holdings in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.